PE20011026A1 - N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida como inhibidores de cinasas dependientes de ciclina - Google Patents
N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida como inhibidores de cinasas dependientes de ciclinaInfo
- Publication number
- PE20011026A1 PE20011026A1 PE2000001347A PE0013472000A PE20011026A1 PE 20011026 A1 PE20011026 A1 PE 20011026A1 PE 2000001347 A PE2000001347 A PE 2000001347A PE 0013472000 A PE0013472000 A PE 0013472000A PE 20011026 A1 PE20011026 A1 PE 20011026A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxazolyl
- methyl
- cycline
- thio
- Prior art date
Links
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- -1 1,1-DIMETHYLETHYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940076005 apoptosis modulator Drugs 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/464,511 US6262096B1 (en) | 1997-11-12 | 1999-12-15 | Aminothiazole inhibitors of cyclin dependent kinases |
| US61662700A | 2000-07-26 | 2000-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011026A1 true PE20011026A1 (es) | 2001-12-02 |
Family
ID=27041008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001347A PE20011026A1 (es) | 1999-12-15 | 2000-12-15 | N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida como inhibidores de cinasas dependientes de ciclina |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1240166B1 (enExample) |
| JP (1) | JP2003516987A (enExample) |
| KR (1) | KR100738132B1 (enExample) |
| CN (1) | CN1433416A (enExample) |
| AR (1) | AR026974A1 (enExample) |
| AT (1) | ATE289306T1 (enExample) |
| AU (1) | AU783719B2 (enExample) |
| BR (1) | BR0016424A (enExample) |
| CA (1) | CA2394552A1 (enExample) |
| CO (1) | CO5261565A1 (enExample) |
| CZ (1) | CZ20022015A3 (enExample) |
| DE (1) | DE60018205T2 (enExample) |
| DK (1) | DK1240166T3 (enExample) |
| EG (1) | EG24168A (enExample) |
| ES (1) | ES2236034T3 (enExample) |
| HK (1) | HK1049661B (enExample) |
| HU (1) | HUP0301032A3 (enExample) |
| IL (2) | IL149755A0 (enExample) |
| MX (1) | MXPA02005870A (enExample) |
| MY (1) | MY125768A (enExample) |
| NO (1) | NO323726B1 (enExample) |
| NZ (1) | NZ519120A (enExample) |
| PE (1) | PE20011026A1 (enExample) |
| PL (1) | PL364921A1 (enExample) |
| PT (1) | PT1240166E (enExample) |
| RU (1) | RU2002119016A (enExample) |
| TW (1) | TWI273103B (enExample) |
| UY (1) | UY26481A1 (enExample) |
| WO (1) | WO2001044242A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6414156B2 (en) * | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
| US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| WO2002010162A1 (en) * | 2000-07-26 | 2002-02-07 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2432799C (en) | 2000-12-21 | 2008-08-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| PT1532145E (pt) | 2002-08-02 | 2007-01-31 | Vertex Pharma | Composiçoes de pirazole úteis como inibidores de gsk-3 |
| US7392929B1 (en) | 2004-07-26 | 2008-07-01 | Zephyros, Inc. | Weldable synthetic material |
| WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| WO2007056163A2 (en) | 2005-11-03 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8236128B2 (en) | 2006-10-26 | 2012-08-07 | Zephyros, Inc. | Adhesive materials, adhesive parts formed therewith and their uses |
| WO2008063933A2 (en) * | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
-
2000
- 2000-11-16 MY MYPI20005385A patent/MY125768A/en unknown
- 2000-12-07 HK HK03100935.5A patent/HK1049661B/en not_active IP Right Cessation
- 2000-12-07 CA CA002394552A patent/CA2394552A1/en not_active Abandoned
- 2000-12-07 MX MXPA02005870A patent/MXPA02005870A/es active IP Right Grant
- 2000-12-07 JP JP2001544732A patent/JP2003516987A/ja not_active Withdrawn
- 2000-12-07 AU AU27264/01A patent/AU783719B2/en not_active Ceased
- 2000-12-07 PT PT00990204T patent/PT1240166E/pt unknown
- 2000-12-07 EP EP00990204A patent/EP1240166B1/en not_active Expired - Lifetime
- 2000-12-07 NZ NZ519120A patent/NZ519120A/en unknown
- 2000-12-07 AT AT00990204T patent/ATE289306T1/de not_active IP Right Cessation
- 2000-12-07 BR BR0016424-0A patent/BR0016424A/pt not_active Application Discontinuation
- 2000-12-07 DE DE60018205T patent/DE60018205T2/de not_active Expired - Fee Related
- 2000-12-07 CZ CZ20022015A patent/CZ20022015A3/cs unknown
- 2000-12-07 ES ES00990204T patent/ES2236034T3/es not_active Expired - Lifetime
- 2000-12-07 IL IL14975500A patent/IL149755A0/xx unknown
- 2000-12-07 RU RU2002119016/04A patent/RU2002119016A/ru unknown
- 2000-12-07 PL PL00364921A patent/PL364921A1/xx not_active Application Discontinuation
- 2000-12-07 WO PCT/US2000/033501 patent/WO2001044242A1/en not_active Ceased
- 2000-12-07 CN CN00818900A patent/CN1433416A/zh active Pending
- 2000-12-07 KR KR1020027007615A patent/KR100738132B1/ko not_active Expired - Fee Related
- 2000-12-07 DK DK00990204T patent/DK1240166T3/da active
- 2000-12-07 HU HU0301032A patent/HUP0301032A3/hu unknown
- 2000-12-09 EG EG20001523A patent/EG24168A/xx active
- 2000-12-14 UY UY26481A patent/UY26481A1/es not_active Application Discontinuation
- 2000-12-14 TW TW089126788A patent/TWI273103B/zh not_active IP Right Cessation
- 2000-12-14 CO CO00095237A patent/CO5261565A1/es not_active Application Discontinuation
- 2000-12-15 AR ARP000106680A patent/AR026974A1/es unknown
- 2000-12-15 PE PE2000001347A patent/PE20011026A1/es not_active Application Discontinuation
-
2002
- 2002-05-20 IL IL149755A patent/IL149755A/en active IP Right Grant
- 2002-06-13 NO NO20022817A patent/NO323726B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011026A1 (es) | N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida como inhibidores de cinasas dependientes de ciclina | |
| PE20010932A1 (es) | N-[5 [[[5-alquil-2-oxazolil] metil] tio]-2-tiazolil]]-carboxamida inhibidores de cinasas dependientes de ciclina | |
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| PE131699A1 (es) | Inhibidores de aminotiazol de cinasas dependientes de ciclina | |
| RU2413723C2 (ru) | Соединения и композиции как модуляторы активированных рецепторов пролифератора пероксисомы | |
| UY24543A1 (es) | Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona | |
| PE20010749A1 (es) | Inhibidores de tirosin-cinasas | |
| KR950702982A (ko) | 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives) | |
| KR970005307A (ko) | 동맥경화 및 황색종의 치료 | |
| KR900016121A (ko) | 소염제 및 퇴화 억제제로서 유용한 치환된 아제티디논 | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| EA199800912A1 (ru) | Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства | |
| ATE293611T1 (de) | Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren | |
| AR029006A1 (es) | Derivados de heterociclos con 5 miembros, su preparacion y su uso como medicamentos | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| CA2636826A1 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| AR030563A1 (es) | N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]carboxamidas inhibidoras de cinasas dependientes de la ciclina y composiciones farmaceuticas que las contienen | |
| EA200400943A1 (ru) | Тиазольные и оксазольные производные, которые модулируют ppar активность | |
| EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
| EP1312601A4 (en) | CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE | |
| RU2010107892A (ru) | Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их | |
| DK0863136T3 (da) | Azetidin- og pyrrolidinderivater | |
| AR027261A1 (es) | Linezolid forma cristalina ii | |
| CL2024004060A1 (es) | Compuestos heterocíclicos inhibidores de axl; composición farmacéutica; uso para tratar cáncer. | |
| EP1314719A4 (en) | BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |